BB5523

BB5523: sourced facts only. name: "BB5523 also shows good activities on VEGFR2 (IC50 = 1.6 nM) and TNIK (IC50 = 0.7 nM) which are crucial for the proliferation of cancer cells." [DOI:10.1158/1538-7445.am2024-603]; target: "BB5523 also shows good activities on VEGFR2 (IC50 = 1.6 nM) and TNIK (IC50 = 0.7 nM) which are crucial for the proliferation of cancer cells." [DOI:10.1158/1538-7445.am2024-603]; target: "BB5523 also shows good activities on VEGFR2 (IC50 = 1.6 nM) and TNIK (IC50 = 0.7 nM) which are crucial for the proliferation of cancer cells." [DOI:10.1158/1538-7445.am2024-603]; developer: "1BroadenBio Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2024-603]; modality: "As a potent and oral available small molecule kinase inhibitor, BB5523 boosts anti-tumor immunity through HPK1 inhibition, while also blocking crucial signaling pathways in tumor micro-environment." [DOI:10.1158/1538-7445.am2024-603]; stage: "BB5523 showed significant tumor-growth inhibition efficacy in TE-8, JIMT-1, B16-F10 and MC38 tumor models." [DOI:10.1158/1538-7445.am2024-603]